1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Anthony J. Olszanski(Fox Chase Cancer Center), Xīn Gào(Qingdao University), John P. Gibbs(Takeda (United States)), Jeffrey J. Raizer(Northwestern University), Chun Li(University of Southern California), Philippe L. Bédard(Princess Margaret Cancer Centre), Jason J. Luke(University of Chicago), Patricia LoRusso(Yale Cancer Center), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Sandip Pravin Patel(University of California San Diego), Min Young Lee(Takeda (United States)), Aniket Joshi, Ruizhe Xu(Takeda (United States)), Y-C. Huang(Takeda (United States)), R. Gregory(Takeda (United States)), Donald P. Orr(Trinity College Dublin), S. Perera(Takeda (United States)), Rachel E. Sanborn(Providence Portland Medical Center)
Cited by 14
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k